Extraesophageal and atypical manifestations of GERD

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue SUPPL. 3, 2004, Pages

  Wong, Wai Man ^a,b   Fass, Ronnie ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Atypical manifestations of GERD; Extraesophageal manifestations of GERD; NCCP; PPI

Indexed keywords

ANTACID AGENT; BOTULINUM TOXIN; HISTAMINE H2 RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR AGONIST; LANSOPRAZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIFEDIPINE; NITRATE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SERTRALINE; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ASPIRATION PNEUMONIA; ASTHMA; BRONCHIECTASIS; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; COUGHING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSPEPSIA; EPIGASTRIC PAIN; ESOPHAGUS INJURY; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HOARSENESS; HUMAN; LARYNGITIS; LARYNX CANCER; LARYNX CARCINOMA; LARYNX DISORDER; LUNG FIBROSIS; NAUSEA; OTITIS; PHARYNGITIS; PRIORITY JOURNAL; PSYCHOTHERAPY; REFLUX ESOPHAGITIS; SINUSITIS; SLEEP APNEA SYNDROME; SLEEP DISORDER; SUBGLOTTIC STENOSIS; THORAX PAIN; TOOTH DISEASE; TREATMENT FAILURE;

EID: 4544250285     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03589.x     Document Type: Conference Paper

References (94)

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County. Minnesota. Gastroenterol. 1997; 112: 1448-56.
2. Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population based study. Am. J. Gastroenterol. 2001; 96: 2905-14.
3. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J. Gastroenterol. Hepatol. 2001; 13: S5-11.
4. Haque M, Wyeth JW, Stace NH, Talley NJ, Green R. Prevalence, severity and associated features of gastrooesophageal reflux and dyspepsia: a population-based study. N Z Med. J. 2000; 113: 178-81.
5. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol. 1999; 231 (Suppl.): 20-8.
6. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann. Med. 1995; 27: 67-70.
7. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand. J. Gastroenterol. 1991; 26: 73-81.
8. Jones RH, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.
9. Frank L, Kleinman L, Ganoczy D et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilisation and quality of life. Dig. Dis. Sci. 2000; 45: 809-18.
10. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol. Ther. 2000; 14: 1589-94.
11. Louis E, DeLooze D, Deprez P et al. Heartburn in Belgium: prevalence, impact on daily life, and utilisation of medical resources. Eur J. Gastroenterol. Hepatol. 2002; 14: 279-84.
12. Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management- the Genval Workshop Report. Gut 1999; 44: S1-S16.
13. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr. Esophageal hypersensitivity may be a major cause of heartburn. Am. J. Gastroenterol. 1999; 94: 628-31.
14. Fass R. Poorly recognized reflux-related symptoms. Eur J. Gastroenterol. Hepatol. 2001; 13: S32-4.
15. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease: an overview. Am. J. Gastroenterol. 2000; 95: S1-S3.
16. Fennerry MB. Extraesophageal gastroesophageal reflux disease - presentation and approach to treatment. Gastroenterol. Clin. North Am. 1999; 28: 861-73.
17. Dekel R, Green C, Quan S, Stephen G, Fass R. The relationship between severity and frequency of symptoms and quality of sleep (QOS) in Patients with gastroesophageal reflux disease (GERD). Gastroenterology 2003; 124: A414.
18. Green C, Dekel R, Quan S, Stephen G, Fass R. The relationship between the extent of esophageal acid exposure and reported quality of sleep. Gastrointest. Endosc. 2003; 57: AB133.
19. Fass R. Noncardiac chest pain. In: GERD/Dyspepsia 1st edn. Philadelphia, PA: Hanley & Belfus, 2004; 183-96.
20. Fass R, Malagon I, Schmulson M. Chest pain of esophageal origin. Current Opinion Gastroenterol. 2001; 17: 376-80.
21. Fass R. Chest pain of esophageal origin. Current Opinion Gastroenterol. 2002; 18: 464-70.
22. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 1993; 38: 1569-80.
23. Mitchell BD, Hazuda HP, Haffner SM, Patterson JK, Stern MP. High prevalence of angina pectoris in Mexican-American men. A population with reduced risk of myocardial infarction. Ann. Epidemiol. 1991; 1: 415-26.
24. Lampe FC, Whincup PH, Wannamethee SG, Ebrahim S, Walker M, Shaper AG. Chest pain on questionnaire and prediction of major ischaemic heart disease events in men. Eur Heart J. 1998; 19: 63-73.
25. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting - a population-based study. Aliment Pharmacol. Ther 2003; 17: 1115-24.
26. Rose G. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull. World Health Organ 1962; 27: 645-58.
27. Wong WM, Lam KF, Cheng C et al. Population based study of noncardiac chest pain in Chinese: prevalence, psychosocial factors and health care utilization. World J. Gastroenterol. 2004; 10: 707-12.
28. Wong WM, Wong BCY. NCCP. An Asian view. Gastroenterol. Clin. North Am. 2004; 33: 125-33.
29. Cherian P, Smith LF, Bardhan KD et al. Esophageal tests in the evaluation of non-cardiac chest pain. Dis Esophagus 1995; 8: 129.
30. Fass R., Fennerty MB, Ofman JJ et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9.
31. Hsia PC, Maher KA, Lewis JH, Cattau EL Jr., Fleischer DE, Benjamin SB. Utility of upper endoscopy in the evaluation of noncardiac chest pain. Gastrointest Endosc 1991; 37: 22-6.
32. Wong WM, Lai KC, Lau CP et al. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol. Ther 2002; 16: 465-71.
33. Dekel R, Martinez-Hawthorne SD, Guillen RJ, Fass R. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J. Clin. Gastroenterol. 2004; 38: 24-9.
34. Achem. SR, Kolts BE, Wears R, Burton L, Richter JE. Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am. J. Gastroenterol. 1993; 88: 187-92.
35. Katz PO, Dalton CB, Richter JE, Wu WC, Castell DO. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann. Intern. Med. 1987; 106: 593-7.
36. Dekel R, Pearson T, Wendel C, De Garmo P, Fennerty MB, Fass R. Assessment of oesophageal motor function in patients with dysphagia or chest pain - the Clinical Outcomes Research Initiative experience. Aliment Pharmacol. Ther 2003; 18: 1083-9.
37. Breumelhof R, Nadorp JH, Akkermans LM, Smout AJ. Analysis of 24-hour esophageal pressure and pH data in unselected patients with noncardiac chest pain. Gastroenterology 1990; 99: 1257-64.
38. Lam HG, Dekker W, Kan G, Breedijk M, Smout AJ. Acute noncardiac chest pain in a coronary care unit. Evaluation by 24-hour pressure and pH recording of the esophagus. Gastroenterology 1992; 102: 453-60.
39. Balaban DH, Yamamoto Y, Liu J et al. Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology 1999; 116: 29-37.
40. Clouse RE, Richter JE, Heading RC et al. Functional esophageal disorders. Gut 1999; 45: II31-II36.
41. Cervero F. Visceral hyperalgesia revisited. Lancet 2000; 356: 1127-8.
42. Fass R, Tougas G. Functional heartburn: The stimulus, the pain and the brain. Gut 2002; 51: 885-95.
43. Richter JE, Obrecht WF, Bradley LA, Young LD, Anderson KO. Psychologic comparison of patients with nut-cracker esophagus and irritable bowel syndrome. Dig Dis Sci. 1986; 31: 131-8.
44. Cannon RO, Quyymi AA, Mincemoyer R. et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl. J. Med. 1994; 330: 1411-7.
45. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig. Dis. 2000; 18: 20-6.
46. Squillace SJ, Young MF, Sanowski RA. Single dose omeprazole as a test for noncardiac chest pain. Gastroenterology 1993; 104: A197.
47. Young MF, Sanowski RA, Talbert GA, Harrison ME, Walker BE. Omeprazole administration as a test for gastroesophageal reflux. Gastroenterology 1992; 102: A192.
48. Pandak WM, Arezo S, Everett S et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J. Clin. Gastroenterol. 2002; 35: 307-14.
49. Xia HHX, Lai KC, Lam SK et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol. Ther. 2003; 17: 369-77.
50. Fass R, Pulliam G, Hayden CW. Patients with non-cardiac chest pain (NCCP) receiving an empirical trial of high dose lansoprazole, demonstrate early symptom response: a double blind, placebo-controlled trial. Gastroenterology 2001; 120: A221.
51. Fass R, Fullerton H, Hayden CW, Garewal HS. Patients with noncardiac chest pain (NCCP) receiving an empirical trial of high dose rabeprazole demonstrate early symptom response: a double-blind, placebo-controlled trial. Gastroenterology 2002; 122: A580.
52. Fass R, Fennerty MB, Johnson C, Camargo L, Sampliner RE. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J. Clin. Gastroenterol. 1999; 28: 36-9.
53. Katz PO, Castell DO. Approach to the patient with unexplained chest pain. Am. J. Gastroenterol. 2000; 95: S4-S8.
54. Fang J, Bjorkman D. A critical approach to noncardiac chest pain: pathophysiology, diagnosis, and treatment. Am. J. Gastroenterol. 2001; 96: 958-68.
55. Achem. SR, Kolts BE, MacMath T et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig. Dis. Sci. 1997; 42: 2138-45.
56. Richter JE, Dalton CB, Bradley LA, Castell DO. Oral nifedipine in the treatment of noncardiac chest pain in patients with nutcracker esophagus. Gastroenterology 1987; 93: 21-8.
57. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92: 1027-36.
58. Varia I, Logue E, O'connor C et al. Randomized trial of sertraline in patients with unexplained chest pain of non-cardiac origin. Am. Heart J. 2000; 140: 367-72.
59. Klimes I, Mayou RA, Pearce MJ, Coles L, Fagg JR. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol. Med. 1990; 20: 605-11.
60. Mayou RA, Bryant BM, Sanders D et al. A controlled trial of cognitive behavioural therapy for non-cardiac chest pain. Psychol. Med. 1997; 27: 1021-31.
61. van Peski-Oosterbaan AS, Spinhoven P, van Rood Y et al. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am. J. Med. 1999; 106: 424-9.
62. Miller LS, Pullela SV, Parkman HP et al. Treatment of chest pain in patients with noncardiac, nonreflux, non-achalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal. Am. J. Gastroenterol. 2002; 97: 1640-6.
63. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD). a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101 (Suppl. 53): 1-78.
64. Wong RKH, Hanson DG, Waring PJ, Shaw G. Am. J. Gastroenterol. 2000; 95: S15-S22.
65. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am. J. Med. 1994; 96: 321-6.
66. Havas T, Huang S, Levy M et al. Posterior pharyngolaryngitis. Double-blind randomized placebo-controlled trial of proton pump inhibitor therapy. Aust. J. Otolaryng 1999; 3: 243-6.
67. Shaker R., Milbrath M, Ren J et al. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995; 109: 1575-82.
68. Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'reflux laryngitis'. Gastroenterology 1991; 100: 305-10.
69. Katz PO. Ambulatory esophageal and hypopharyngeal pH monitoring in patients with hoarseness. Am. J. Gastroenterol. 1990; 85: 38-40.
70. Wilson JA, White A, von Haacke NP et al. Gastroesophageal reflux and posterior laryngitis. Ann. Otol. Rhinol. Laryngol. 1989; 98: 405-10.
71. Mittal RK, Stewart WR, Schirmer BD. Effect of a catheter in the pharynx on the frequency of transient lower esophageal sphincter relaxations. Gastroenterology 1992; 103: 1236-40.
72. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am. J. Gastroenterol. 2001; 96: 979-83.
73. Irwin RS, Boulet LP, Cloutier MM et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S-181S.
74. Irwin RS & Richter JE. Gastroesophageal reflux and chronic cough. Am. J. Gastroenterol. 2000; 95: S9-14.
75. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am. Rev. Respir. Dis. 1990; 141: 640-7.
76. Irwin RS, Zawacki JK, Curley FJ, French CL, Hoffman PJ. Chronic cough as the sole presenting manifestation of gastroesophageal reflux. Am. Rev. Respir. Dis. 1989; 140: 1294-300.
77. Waring JP, Lacayo L, Hunter J, Katz E, Suwak B. Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. Dig. Dis. Sci. 1995; 40: 1093-7.
78. Smyrnios NA, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest 1995; 108: 991-7.
79. Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am. J. Gastroenterol. 1999; 94: 3131-8.
80. Perrin-Fayolle M, Bel A, Kofman J et al. Asthma and gastro-esophageal reflux. Results of a survey over 150 cases. Poumon Coeur 1980; 36: 225-30.
81. Sontag SJ, O'Connell S, Khandelwal S et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99: 613-20.
82. Field SK, Underwood M, Brant R., Cowie RL. Prevalence of gastroesophageal reflux symptoms in asthma. Chest 1996; 109: 316-22.
83. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755-60.
84. Harding SM, Sontag SJ. Asthma and gastroesophageal reflux. Am. J. Gastroenterol. 2000; 95: S23-32.
85. Mansfield LE & Stein MR. Gastroesophageal reflux and asthma: a possible reflex mechanism. Ann. Allergy 1978; 41: 224-6.
86. Mansfield LE, Hameister HH, Spaulding HS, Smith NJ, Glab N. The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention. Ann. Allergy 1981; 47: 431-4.
87. Wright RA, Miller SA, Corsello BF. Acid-induced esophagobronchial-cardiac reflexes in humans. Gastroenterology 1990; 99: 71-3.
88. Schan CA, Harding SM, Haile JM, Bradley LA, Richter JE. Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology. Chest 1994; 106: 731-7.
89. Tuchman DN, Boyle JT, Pack AI et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87: 872-81.
90. Hamamoto J, Kohrogi H, Kawano O et al. Esophageal stimulation by hydrochloric acid causes neurogenic inflammation in the airways in guinea pigs. J. Appl. Physiol. 1997; 82: 738-45.
91. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am. J. Med. 1996; 100: 395-405.
92. Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature. Chest 1998; 114: 275-83.
93. Field SK, Gelfand GA, McFadden SD. The effects of antireflux surgery on asthmatics with gastroesophageal reflux. Chest 1999; 116: 766-74.
94. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 1998; 124: 28-32.